Long-Term Safety and Efficacy of Natalizumab in Relapsing-Remitting Multiple Sclerosis: Impact on Quality of Life

Patient Related Outcome Measures
doi 10.2147/prom.s41768
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting

Journal of Neurology & Neurophysiology
2015English

Real-Life Effectiveness of Natalizumab in Relapsing-Remitting Multiple Sclerosis (Rrms): A Registry Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
Chemical HealthPharmacologySafetyMedicineToxicologySafety ResearchPharmaceutics
2007English

Long-Term Evaluation of NEDA-3 Status in Relapsing-Remitting Multiple Sclerosis Patients After Switching From Natalizumab to Fingolimod

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2018English

The Impact of Pain and Other Symptoms on Quality of Life in Women With Relapsing-Remitting Multiple Sclerosis

Journal of Neuroscience Nursing
EndocrineMedicalAutonomic SystemsSurgical NursingNeurologySurgery
2009English

Pnd155 - Reduced Relapse Rates and Improved Quality of Life for Relapsing-Remitting Multiple Sclerosis (Rrms) Patients Treated With Natalizumab vs Injectable Therapies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Long-Term Safety and Real-World Effectiveness of Fingolimod in Relapsing Multiple Sclerosis

Patient Related Outcome Measures
2017English

Pnd12 - Natalizumab Versus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis

Neurotherapeutics
NeurologyPharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy